More tools:Markets·Screener·Research·Chat

Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) Financial Statements

Rhythm Pharmaceuticals, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG007DLZ629
XNAS · usd
101.80▼ 0.94 (-0.91%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close102.74
Day's Range99.41 – 103.31
52-Week Range73.75 – 122.20
Volume512.5K
Avg Volume597.9K
Share Statistics
Shares Outstanding
Employees414
ExchangeXNAS
Listed2017-10-05
Share count as of August 1, 2026
Loading Income Statement…
Key questions about Rhythm Pharmaceuticals, Inc. Common Stock (RYTM)
What is Rhythm Pharmaceuticals, Inc. Common Stock's Market Cap?
Rhythm Pharmaceuticals, Inc. Common Stock's Market Cap is $7.0B, based on as-reported figures from SEC (XBRL) filings.
What is Rhythm Pharmaceuticals, Inc. Common Stock's Enterprise Value?
Rhythm Pharmaceuticals, Inc. Common Stock's Enterprise Value is $6.9B, based on as-reported figures from SEC (XBRL) filings.
What is Rhythm Pharmaceuticals, Inc. Common Stock's Price / Sales?
Rhythm Pharmaceuticals, Inc. Common Stock's Price / Sales is 29.2×, based on as-reported figures from SEC (XBRL) filings.
What is Rhythm Pharmaceuticals, Inc. Common Stock's EV / Revenue?
Rhythm Pharmaceuticals, Inc. Common Stock's EV / Revenue is 28.8×, based on as-reported figures from SEC (XBRL) filings.
What is Rhythm Pharmaceuticals, Inc. Common Stock's EV / EBITDA?
Rhythm Pharmaceuticals, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Rhythm Pharmaceuticals, Inc. Common Stock's Revenue (TTM)?
Rhythm Pharmaceuticals, Inc. Common Stock's Revenue (TTM) is $239.9M, based on as-reported figures from SEC (XBRL) filings.
What is Rhythm Pharmaceuticals, Inc. Common Stock's Net Income (TTM)?
Rhythm Pharmaceuticals, Inc. Common Stock's Net Income (TTM) is -$205.3M, based on as-reported figures from SEC (XBRL) filings.
What is Rhythm Pharmaceuticals, Inc. Common Stock's EBITDA?
Rhythm Pharmaceuticals, Inc. Common Stock's EBITDA is -$200.1M, based on as-reported figures from SEC (XBRL) filings.
What is Rhythm Pharmaceuticals, Inc. Common Stock's Diluted EPS (TTM)?
Rhythm Pharmaceuticals, Inc. Common Stock's Diluted EPS (TTM) is -2.98, based on as-reported figures from SEC (XBRL) filings.
What is Rhythm Pharmaceuticals, Inc. Common Stock's EBITDA Margin?
Rhythm Pharmaceuticals, Inc. Common Stock's EBITDA Margin is -83.4%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Total revenues
YoY growth+46.9%+83.8%+36.9%+54.3%
Costs and expenses:
Cost of sales
Research and development
Selling, general, and administrative
Total costs and expenses
% of revenue168.1%187.1%182.2%202.6%
Loss from operations
% of revenue-68.1%-87.1%-82.2%-102.6%
Other income (expense):
Other income (expense), net
Interest expense
Interest income
Total other expense, net
Loss before income taxes
Provision for income taxes
Net loss
% of revenue-69.2%-92.6%-83.0%-103.1%
Accrued dividends on convertible preferred stock
Net loss attributable to common stockholders
Net loss per share attributable to common stockholders, basic (in dollars per share)
Net loss per share attributable to common stockholders, diluted (in dollars per share)